Drug delivery to brain tumours: Challenges and progress

Expert Opinion on Drug Delivery

Volumn 3, Issue 4, 2006, Pages 499-509

  Ningaraj, Nagendra S ^a  

^a MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Blood brain barrier; Blood brain tumour barrier; Brain tumour; Drug delivery; Magnetic resonance imaging; Potassium channels

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; BLOOD BRAIN BARRIER; BRAIN TUMOR; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 39049194160     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.4.499     Document Type: Review

References (56)

1. RICH JN, BIGNER DD: Development of novel targeted therapies in the treatment of malignant glioma. Nat. Rev. Drug Discov. (2004) 3:430-446. •• This review article highlights the importance of EGFR as a molecular target for brain cancer treatment. It also reviews studies on EGFR amplification, overexpression or mutation in glioblastomas.
2. PARDRIDGE WM: Drug targeting, drug discovery, and brain drug development. In: Brain Drug Targeting: the Future of Brain Drug Development. Cambridge University Press, Cambridge, UK (2001):1-13.
3. STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352:987-996. (Pubitemid 40349501)
4. PARDRIDGE WM, BOADO RJ, BLACK KL, CANCILLA PA: Blood-brain barrier and new approaches to brain drug delivery. West J. Med. (1992) 156:281-286.
5. GROOTHUIS DR: The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncol. (2000) 2:45-59.
6. PARDRIDGE WM: Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin. Biol. Ther. (2004) 4(7):1103-1113. (Pubitemid 38937552)
7. LI JY, BOADO RJ, PARDRIDGE WM: Blood-brain barrier genomics. J. Cereb. Blood Flow Metab. (2001) 21:61-68. (Pubitemid 32016840)
8. BECKER AJ, CHEN J, ZIEN A et al.: Correlated stage- and subfield-associated hippocampal gene expression patterns in experimental and human temporal lobe epilepsy. Eur. J. Neurosci. (2003) 18:2792-2802. (Pubitemid 37542132)
9. FERRARI M: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer (2005) 5:161-171. (Pubitemid 40314948)
10. BAZAN NG, MARCHESELLI VL, COLE-EDWARDS K: Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann. NY Acad. Sci. (2005) 1053:137-147. (Pubitemid 43031090)
11. DOOLITTLE ND, ABREY LE, BLEYERWA et al.: New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin. Cancer Res. (2005) 11:421-428. (Pubitemid 40116864)
12. FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. (1995) 1:27-31.
13. FIDLER IJ, YANO S, ZHANG RD, FUJIMAKI T, BUCANA CD: The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. (2002) 3:53-57. (Pubitemid 34121146)
14. NINGARAJ NS, RAO M, HASHIZUME K, ASOTRA K, BLACK KL: Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J. Pharmacol. Exp. Ther. (2002) 301:838-851. (Pubitemid 34595072)
15. NINGARAJ NS, RAO M, BLACK KL: Calcium-dependent potassium channels as a target protein for modulation of the blood-brain tumor barrier. Drug News Perspect. (2003) 16:291-298. (Pubitemid 37176217)
16. NINGARAJ NS, RAO MK, BLACK KL: Adenosine 5′-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res. (2003) 63:8899-8911. •• This research article describes a novel cellular mechanism for KATP-mediated BTB permeability increase. This novel mechanism involves the accelerated formation of pinocytotic vesicles, which can transport drugs across the BTB. This article also explains why the KATP channels are a potential target for biochemical modulation of BTB permeability to increase antineoplastic drug delivery selectively to brain tumours. (Pubitemid 38064070)
17. BALL HJ, MCPARLAND B, DRIUSSI C, HUNT NH: Isolating vessels from the mouse brain for gene expression analysis using laser capture microdissection. Brain Res. Brain Res. Protoc. (2002) 9:206-213. (Pubitemid 34756723)
18. XU BJ, CAPRIOLI RM, SANDERS ME, JENSEN RA: Direct analysis of laser capture microdissected cells by MALDI mass spectrometry. J. Am. Soc. Mass Spectrom (2002) 13:1292-1297. (Pubitemid 36875983)
19. AGARWALA SS, KIRKWOOD JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist (2000) 5:144-151. (Pubitemid 30238234)
20. GULLICK WJ: Update on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancer. Breast Cancer Res. (2001) 3:390-394.
21. GOLDENBERG MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. (1999) 21:309-318. (Pubitemid 29157789)
22. COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. (1999) 17:2639-2648. (Pubitemid 29415219)
23. MENARD S, TAGLIABUE E, CAMPIGLIO M, PUPA SM: Role of HER2 gene overexpression in breast carcinoma. J. Cell. Physiol. (2000) 182:150-162. (Pubitemid 30022667)
24. RUOSLAHTI E: Specialization of tumour vasculature. Nat. Rev. Cancer (2002) 2:83-90. (Pubitemid 37328795)
25. FISHMAN RA, CHRISTY NP: Fate of adrenal cortical steroids following intrathecal injection. Neurology (1965) 15:1-6.
26. RAO M, NINGARAJ N, YAMAMOTO V, BLACK KL: Activation of calcium-dependent potassium channels elicits selective glioma cell death. AACR-NCI-EORTC International Conference (2001) 312:64.
27. BLACK KL, NINGARAJ NS: Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control (2004) 11:165-173. (Pubitemid 38758221)
28. PARDRIDGE WM: Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. Curr. Opin. Drug Discov. Devel. (2003) 6:683-691. (Pubitemid 37287937)
29. FELLNER S, BAUER B, MILLER DS et al.: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. (2002) 110:1309-1318. (Pubitemid 35285757)
30. AYALASOMAYAJULA SP, KOMPELLA UB: Drug efflux pumps: challenges and opportunities. IDrugs (2000) 3(2):148-149.
31. BREEDVELD P, PLUIM D, CIPRIANI G et al.: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. (2005) 65:2577-2582. (Pubitemid 40490054)
32. AWASTHI S, HALLENE KL, FAZIO V et al.: RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci. (2005) 6:61. (Pubitemid 41554978)
33. LIU X, CHEN C: Strategies to optimize brain penetration in drug discovery. Curr. Opin. Drug Discov. Devel. (2005) 8:505-512. (Pubitemid 40917412)
34. REGINA A, DEMEULE M, LAPLANTE A et al.: Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev. (2001) 20:13-25. (Pubitemid 34074674)
35. HEIMANS JJ, VERMORKEN JB, WOLBERS JG et al.: Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann. Oncol. (1994) 5:951-953.
36. DONELLI MG, ZUCCHETTI M, D'INCALCI M: Do anticancer agents reach the tumor target in the human brain? Cancer Chemother. Pharmacol. (1992) 30:251-260.
37. KRIZANAC-BENGEZ L, MAYBERG MR, JANIGRO D: The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis and pathophysiology. Neurol. Res. (2004) 26:846-853. (Pubitemid 39628562)
38. SKOLD MK, VON GERTTEN C, SANDBERG-NORDQVIST AC, MATHIESEN T, HOLMIN S: VEGF and VEGF receptor expression after experimental brain contusion in rat. J. Neurotrauma (2005) 22:353-367. (Pubitemid 40434684)
39. LASSMAN AB: Molecular biology of gliomas. Curr. Neurol. Neurosci. Rep. (2004) 4:228-233. (Pubitemid 38899076)
40. KALLMANN BA, WAGNER S, HUMMEL V et al.: Characteristic gene expression profile of primary human cerebral endothelial cells. FASEB J. (2002) 16:589-591.
41. ASOTRA K, NINGARAJ N, BLACK KL: Measurement of blood-brain and blood-tumor barrier permeabilities with [14C]-labeled tracers. Methods Mol. Med. (2003) 89:177-190.
42. 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. (1999) 5:309-317.
43. REYDERMAN L, STATKEVICH P, THONOOR CM, PATRICK J, BATRA VK, WIRTH M: Disposition and pharmacokinetics of temozolomide in rat. Xenobiotica (2004) 34:487-500. (Pubitemid 38901458)
44. FUNG LK, SHIN M, TYLER B, BREM H, SALTZMAN WM: Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm. Res. (1996) 13:671-682. (Pubitemid 26156217)
45. VOGELBAUM MA: Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J. Neurooncol. (2005) 73:57-69. (Pubitemid 40823269)
46. LI C, HALL WA, JIN N, TODHUNTER DA, PANOSKALTSIS-MORTARI A, VALLERA DA: Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng. (2002) 15:419-427. (Pubitemid 34601734)
47. CHECKLEY D, TESSIER JJ, WEDGE SR et al.: Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magn. Reson. Imaging (2003) 21:475-482. (Pubitemid 36899079)
48. ROBERTS TP, CHUANG N, ROBERTS HC: Neuroimaging: do we really need new contrast agents for MRI? Eur. J. Radiol. (2000) 34:166-178. (Pubitemid 30601691)
49. KNOPP MV, RUNGE VM, ESSIG M et al.: Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology (2004) 230:55-64. (Pubitemid 37549783)
50. ROBINSON SP, MCINTYRE DJ, CHECKLEY D et al.: Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br. J. Cancer (2003) 88:1592-1597. (Pubitemid 36713788)
51. YANKEELOV TE, KASISOMAYAJULA K, NINGARAJ N, PRICE RR, GORE G. Correlation between quantitative autoradiography and the reference region model of DCE- MRI. ISMRM Thirteenth Annual Meeting 7-13 May, Miami Beach, FL, USA (2005):2749.
52. BLACK KL, CLOUGHESY T, HUANG SC et al.: Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J. Neurosurg. (1997) 86:603-609. (Pubitemid 27138628)
53. HASHIZUME K, BLACK KL: Increased endothelial vesicular transport correlates with increased blood-tumor barrier permeability induced by bradykinin and leukotriene C4. J. Neuropathol. Exp. Neurol. (2002) 61:725-735. • The authors of this paper have for the first time shown that bradykinin and leukotriene C4 could increase molecular transport across the BTB. These agents trigger pinocytotic vesicular transport across the BTB, and these transport vesicles may enhance drug transport across the BTB.
54. WARREN K, GERVAIS A, AIKIN A, EGORIN M, BALIS FM: Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother. Pharmacol. (2004) 54:206-212. (Pubitemid 39141736)
55. LEE G, BENDAYAN R: Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm. Res. (2004) 21:1313-1330. (Pubitemid 39149646)
56. FARACI FM, HEISTAD DD: Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol. Rev. (1998) 78:53-97. (Pubitemid 28070975)